Bio-Rad Laboratories, Inc.

HOLMDEL, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management and biometric authentication technologies, today announced that The Nasdaq Stock Market LLC has notified it that the trading of its common stock will recommence on the Nasdaq Capital Market effective with markets' opening on Wednesday, July 8, 2026.

globenewswire.com - 2026-07-07 07:58:00

New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced its participation in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026.

globenewswire.com - 2026-07-02 08:00:00

BIO-key (BKYI) a global leader in biometric-powered identity & access management to participate at Jordan Banking Cybersecurity Workshop in Amman, July 6.

globenewswire.com - 2026-07-02 04:00:00

I assign a "Buy" rating to Bio-Rad Laboratories, citing activist involvement. Elliott's entry signals meaningful re-rating potential, assuming further operational improvements; BIO is already shifting M&A focus to revenue-generating bolt-ons and rationalizing R&D spend. The potential monetization of BIO's Sartorius stake, worth over $5 billion, appears more likely with Elliott's involvement, since the activist is also a shareholder of Sartorius.

seekingalpha.com - 2026-07-02 01:33:05

On June 25, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 6.5% to $298.29. This movement comes in the context of a 52-week range between $235.01 and $343.12,

gurufocus.com - 2026-06-25 18:48:00

41 local tech firms, institutes and university spin-offs head to San Diego to forge global partnerships, reinforcing the city's status as international healthcare innovation hub HONG KONG SAR/SAN DIEGO, UNITED STATES - Media OutReach Newswire - 24 June 2026 - Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK as co-organiser, the Hong Kong Trade Development Council (HKTDC) as supporting organisation, and five renowned local universities - The University of Hong Kong, The Chinese University of Hong Kong, The Hong Kong University of Science and Technology, The Hong Kong Polytechnic University and City University of Hong Kong - to form the city's largest-ever delegation of life and health technology innovators to the BIO International Convention 2026 (BIO 2026) in San Diego, from June 22 to 25. In collaboration with InvestHK and HKTDC, HKSTP led a delegation of 41 park companies, institutes and spin-offs from five renowned local universities to showcase the Hong Kong's life and health technology innovations at BIO 2026 in San Diego. Building on last year's momentum, the 2026 Hong Kong delegation doubled the size of the Hong Kong Pavilion, expanding to a record of 41 organisations from HKSTP, including partner companies, research institutes, and for the first time with top five universities spin-offs. This landmark presence showcased Hong Kong's deep strength across AI-enabled biotech, therapeutics, diagnostics, and pharma innovation, with potential outstanding "First-in-Class" and "Best-in-Class" assets. The delegation underscores the city's leading role as Asia's largest and the world's second largest fundraising hub for the biotechnology sector. Mr. Terry Wong, CEO of HKSTP, said, "BIO 2026 is a premier platform to showcase Hong Kong's groundbreaking innovation, deepen partnerships, and open new pathways into global healthcare markets. As a super-connector, Hong Kong is uniquely positioned to bridge global innovators with opportunities across Asia and beyond. With strong R&D capabilities backed by world-class universities—five ranked among the QS Top 100, including two with medical schools now placed in the global top 20—Hong Kong's biotech and medical research excellence is increasingly recognised worldwide. As the city's innovation ecosystem orchestrator, HKSTP brings together talent, capital, research institutions, clinical partners, and industry leaders to accelerate the journey from discovery to impact. We will continue to empower life and health technology ventures, translating innovation breakthroughs into life-changing solutions that benefit communities around the world." HKSTP and P ark Companies A dvanced in C ross-border I nnovation and M arket E xpansion A key highlight of BIO 2026 is witnessing the signing of three major strategic partnerships: LabCentral -- HKSTP signed an MOU with one of the largest global non - profit biotech incubators, supporting life sciences startups with high-impact lab infrastructure and scientific community programmes. The collaboration will deepen ties between the U.S. and Hong Kong life sciences ecosystems through startup support, ecosystem engagement, and co-developed programmes, events and strategic initiatives. It will also help connect startups, investors, corporate partners and research institutions, creating stronger pathways for cross-border innovation and commercialisation. Immuno Cure – the developer of the first-in-human novel therapeutic HIV vaccine ICVAX – announced its collaboration with OPIS, an international Contract Research Organization (CRO), at BIO 2026. Leveraging OPIS's full-service, multi-country clinical trial expertise and regulatory knowledge, the partnership will support overseas clinical trial execution and establish a global framework to prepare for international expansion. Zhaoke Ophthalmology signed an MOU with Laboratório Teuto, the first company to produce generic medicines and OTCs (Over the Counter – Prescription Exempt Medicines) in Brazil, to explore cross-border cooperation in ophthalmology. This is Zhaoke's first strategic MOU in Brazil market. Leveraging its innovative pipeline and Teuto's commercial network in Brazil, the partnership aims to bring advanced eye care treatments to Latin American patients while demonstrating the globalisation of Hong Kong-born biotech innovation. Beyond the BIO 2026 Hong Kong Pavilion, HKSTP CEO Mr Terry Wong attended the "Translating Innovation Across Borders: Creating Global Gateways for Biotech Startups" panel sharing session. Mr. Wong shared his insights on cutting-edge biotech trends, Hong Kong's strengths on life and health tech development, and HKSTP's role in building a global bridge for nurturing global startup expansion, sustainable innovation and collaboration. Furthermore, HKSTP and five Hong Kong university delegates visited the Salk Institute, home to six Nobel Laureates during BIO 2026 to explore partnerships and shape global biotech momentum through collaborative platforms. HKSTP, in collaboration with InvestHK as co-organiser, HKTDC as the supporting organisation, and powered by the Hong Kong Economic and Trade Office in San Francisco, hosted a Global Mixer during the exhibition. Industry leaders, incubators, and venture capital firms – including Bayer Pharmaceuticals, Johnson & Johnson Innovation, LabCentral, Roche, Simcere Pharmaceutical, and T.Rx Capital – were invited to join the judging panel for startup pitching sessions. The Pavilion also featured executive sharing and curated networking events for commercialisation, licensing, partnerships, investment and international market expansion. Global recognition at Biomedical Pitch Competition In the lead-up to BIO 2026, HKSTP actively drove engagement across the biotech sector and co-organised the 2026 Biomedical Pitch Competition with the Boston Capital Investment Club in Boston on May 23 and 24. Competing against around 170 biotechnology companies worldwide, HKSTP park company Meta Pharmaceuticals (HK) Limited won Third Place for its next-generation autoimmune therapeutics. The recognition underscores the strength of Hong Kong's biotech pipeline and HKSTP's commitment to translational medicine, commercialisation and globally scalable healthcare solutions. HK's biotech ecosystem rises to another level Hong Kong continues to expand its global healthcare footprint as the world's second-largest biotech fundraising hub. As Hong Kong's flagship innovation and technology ecosystem, HKSTP is home to more than 300 life and health technology companies and helps innovators turn pioneering ideas into real-world impact. Its ecosystem connects capital, talent, infrastructure and market access across the biotech innovation journey. Hashtag: #HKSTPThe issuer is solely responsible for the content of this announcement. Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 17,000 research professionals and over 2,500 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at www.hkstp.org.

thenewswire.com - 2026-06-24 06:25:00

U.S. biotechnology industry trade group BIO worked with the Food and Drug ​Administration on plans announced on Monday to speed ‌clinical trials and expects the next initiative will aim to standardize the agency's review of drug applications, CEO John Crowley ​said on Tuesday.

reuters.com - 2026-06-23 16:34:30

Bio-Rad Laboratories offers high profitability and a liquid balance sheet with a current ratio above 5x. Charles River Laboratories International maintains a leading scale in drug discovery services with over 19,000 employees globally.

fool.com - 2026-06-22 17:44:44

ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the 2026 BIO International Convention taking place this week in San Diego, California.

globenewswire.com - 2026-06-22 16:03:00

"Not Just Reducing, But Designing Better Taste" CHICAGO and  DOWNERS GROVE, Ill., June 22, 2026 /PRNewswire/ -- CJ BIO will participate in IFT FIRST 2026, taking place July 13–15, 2026, at McCormick Place in Chicago.

prnewswire.com - 2026-06-22 11:39:00

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster. Spanning AI-enabled research, clinical development and advanced manufacturing, these investments reinforce Thermo Fisher's role as a trusted strategic provider of integrated.

businesswire.com - 2026-06-22 08:30:00

Albuquerque, NM, June 18, 2026 (GLOBE NEWSWIRE) -- A delegation of economic development, research, healthcare, and industry leaders will represent New Mexico's growing bioscience sector at the BIO International Convention, taking place June 22–25, 2026, in San Diego, California. Led by the Albuquerque Regional Economic Alliance (AREA), the delegation will promote New Mexico's bioscience industry, highlight the state's innovation ecosystem, and connect with companies, investors, and industry leaders from around the globe.

globenewswire.com - 2026-06-18 14:45:00

President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health

globenewswire.com - 2026-06-18 09:20:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millions of patients worldwide still lack access to vital medicines. At BIO International Convention 2026, taking place June 22-25 at the San Diego Convention Center, Fujifilm's Life Sciences group will showcase how its integrated global ecosystem is helping biopharmaceutical innovators accelerate the path from discovery to delivery. The company's expanding life sciences portfolio supports therapeutics from discovery to commercialization, serving as “Partners.

businesswire.com - 2026-06-18 09:00:00

Company to Showcase Integration of AI, Digital Batch Records, and Intelligent Robotics to Accelerate Pharmaceutical Manufacturing AGOURA HILLS, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) today announced the launch of its artificial intelligence ("AI") powered good manufacturing practices ("GMP") manufacturing services platform (the "Platform") at the 2026 BIO International Convention in San Diego, California.

globenewswire.com - 2026-06-18 08:00:00

Biometric authentication provider BIO-key's (BKYI) CEO will participate in a webcast fireside chat at Maxim Group's Defense Tech Conf. 6-25 at 4pm, track 2

globenewswire.com - 2026-06-18 07:59:00

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details: Session: Company Presentation Date/Time: Wednesday, June 24, 11:45 AM Location: Theater 3 BioHarvest Sciences' presentation will showcase its proprietary Botanical Synthesis™ platform, which enables the production of plant-derived compounds with pharmaceutical-grade precision, consistency, and commercial scalability, opening new possibilities in drug discovery, active pharmaceutical ingredients, and next-generation therapeutics.

newsfilecorp.com - 2026-06-18 07:30:00

Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease RAMAT GAN, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced its participation in the BIO International Convention 2026, to be held June 22–25, 2026, in San Diego, California.

globenewswire.com - 2026-06-17 07:00:00

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that Company management, including the Company's Chief Executive Officer, Ilan Hadar, and the Company's Chief Financial Officer, Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention, taking place on June 22-25 in San Diego, CA.  

globenewswire.com - 2026-06-16 16:30:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California. “We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxic.

businesswire.com - 2026-06-16 09:28:00

Introduces key products including an integrated brain imaging analysis solution for Alzheimer's disease treatment decision-making Expands partnering efforts with global pharmaceutical and biotech companies as well as potential customers, while introducing its ICL services SEOUL, South Korea, June 16, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it will participate in the 2026 BIO International Convention (BIO USA), which will be held in San Diego, the United States, from June 22 to 25. At this year's BIO USA, Neurophet will showcase Neurophet AQUA AD Plus, an integrated brain imaging analysis solution designed to support treatment decision-making for Alzheimer's disease therapies.

prnewswire.com - 2026-06-16 09:00:00

HOLMDEL, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc.  (OTC Markets: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced today that it has received a notification letter from The Nasdaq Stock Market, LLC informing the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission, due to the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026.

globenewswire.com - 2026-06-10 17:00:00

KUALA LUMPUR, MALAYSIA, June 04, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; the “Company”) today announced that it entered into a Business Combination Agreement (“BCA”) with Future NRG Sdn. Bhd. (“Future NRG”) in an all stock share exchange transaction. Future NRG is a Malaysia-based technology integrator and project developer operating at the forefront of innovative and sustainable medical waste management, for healthcare waste generators including clinics, dental practices, veterinary clinics, dialysis centers, laboratories, and factories, offering advanced waste-to-energy and waste-to-resource projects using advanced, market-proven clean technology. Upon completion of the share exchange, which is subject to approval by BGMS and Future NRG's shareholders, the combined company is expected to continue operating under the name Bio Green Med Solution, Inc. and continue trading on the Nasdaq Capital Market under the ticker symbol “BGMS”.

globenewswire.com - 2026-06-04 16:10:00

BIO-key's RedChip Future Tech Investor Conference Presentation to Webcast Wed. June 10 at 3pm ET URL: https://www.redchip.com/webinar/redchip/89763628854.

globenewswire.com - 2026-06-04 07:58:00

Bio-Rad Laboratories, Inc. (BIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-03 12:41:59

Kelowna, British Columbia - June 3 , 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms , announces that it is attending the BIO International Convention (“BIO”) from June 22-25 in San Diego, CA . Lexaria's attendance at last year's 2025 BIO convention served as a catalyst for its greatly expanded business development (“BD”) program that is now starting to deliver positive results and which Lexaria intends to build upon at this year's BIO conference.   “We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference,” said Richard Christopher, CEO of Lexaria Bioscience. “New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss.”

thenewswire.com - 2026-06-03 09:25:00

Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is a potential target for therapy and prevention of cancer Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs) PONTE VEDRA, Fla., June 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced its participation in the BIO International Convention 2026 Partnering Event (BIO 2026) taking place June 22–25, 2026, at the San Diego Convention Center.

globenewswire.com - 2026-06-03 09:00:00

BIO-key Delivers Phishing-Resistant Biometric Security to Alabama's AOD Federal Credit Union via Strategic IT Solutions Partnership with Provider BlueAlly

globenewswire.com - 2026-06-02 12:48:00

BIO-key Delivers Phishing-Resistant Biometric Security to Alabama's AOD Federal Credit Union via Strategic IT Solutions Partnership with Provider BlueAlly

globenewswire.com - 2026-06-02 07:59:00

On May 28, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 4.2% today, closing at a price of $318.22. The stock has shown significant performance over the last

gurufocus.com - 2026-05-28 18:37:00

Elliott Investment Management has reportedly built a sizable stake in Bio-Rad Laboratories (BIO), putting fresh activist pressure on a life-science tools suppli

gurufocus.com - 2026-05-22 12:25:00

Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure SAN ANTONIO, May 19, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute radiation syndrome (ARS) to senior officials from the U.S. Department of War and the Biomedical Advanced Research and Development Authority (BARDA) in a joint briefing held on May 14, 2026. The session was Valion Bio's second engagement with senior Department of War officials, following the Company's April 28, 2026, Pentagon briefing on Entolimod.

prnewswire.com - 2026-05-19 16:38:00

Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-19 10:40:56

HOLMDEL, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (OTC Markets: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced its first quarter (Q1'26) results and first half of 2026 (1H'26) outlook.

globenewswire.com - 2026-05-18 07:59:00

Activist investor Elliott Investment Management has built a sizeable stake ​in U.S. diagnostics supplier Bio-Rad Laboratories , and plans ‌to push the company to boost its underperforming stock price, the Wall Street Journal reported on Sunday.

reuters.com - 2026-05-17 21:38:19

Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.

wsj.com - 2026-05-17 20:03:00

KUALA LUMPUR, MALAYSIA, May 14, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced first quarter financial results and provided a business update.

globenewswire.com - 2026-05-14 16:15:00

First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity Bioworks Conference Call to be Held Today at 1:30 PM PT / 4:30 PM ET SAN ANTONIO  , May 14, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company, today reported financial results for the three months ended March 31, 2026 — the company's first full reporting quarter under its new corporate identity — and provided a business update on the continued advancement of its Entolimod platform, ongoing engagement with U.S. government agencies, and continued integration of wholly owned manufacturing subsidiary Velocity Bioworks. First Quarter 2026 Highlights and Subsequent Events Completed corporate transformation, including the change of the company's legal name from Tivic Health Systems, Inc. to Valion Bio, Inc. and the change of the company's Nasdaq listing symbol from TIVC to VBIO, consolidating the company's identity as a focused clinical-stage immunotherapeutics platform.

prnewswire.com - 2026-05-14 16:05:00

HOLMDEL, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, today announced that it has received written notification from The Nasdaq Stock Market LLC that the trading of its common stock will be suspended on Nasdaq effective with markets' close today, Tuesday, May 12, 2026.

globenewswire.com - 2026-05-12 16:01:00

HOLMDEL, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, will host its Q1'26 investor call and webcast on Monday, May 18th at 10 a.m.

globenewswire.com - 2026-05-12 07:59:00

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following upcoming investor conferences: 2026 RBC Capital Markets Global Healthcare Conference Format: Fireside chat and one-on-one investor meetings Participants: Roop K. Lakkaraju, Chief Financial Officer Date and Time: Tuesday, May 19, 2026, at 8:30 AM Eastern Time; a live webc.

businesswire.com - 2026-05-08 09:00:00

Initial Study to Evaluate Entolimod™ for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome — an Indication for Which No Currently Approved or Stockpiled Countermeasure Has Demonstrated Efficacy SAN ANTONIO, May 5, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) (formerly Tivic Health Systems, Inc.), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced it has received the first study protocol under its previously announced non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health. Under the agreement — valued at up to $7 million — NIAID will fully fund the in vivo studies required to support the Company's Biologics License Application (BLA) for Entolimod™ under the FDA's Animal Rule pathway, with the agency further committed to co-navigate the FDA submission process alongside Valion Bio upon favorable study outcomes.

prnewswire.com - 2026-05-05 08:00:00

Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

zacks.com - 2026-05-04 10:16:12

On May 01, 2026, Bio-Rad Laboratories Inc (BIO) shares fell 8.4% today, bringing the current price to $256.55. This decline is significant in the context of the

gurufocus.com - 2026-05-01 17:29:00

Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-01 06:01:34

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $1.89 per share, missing the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.54 per share a year ago.

zacks.com - 2026-04-30 19:26:42

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "Our first-quarter results reflected our resolve in navigating a dynamic environment. Despite external headwinds including challenging academic end markets and conflict escalation in the.

businesswire.com - 2026-04-30 16:15:00

Company Presented Entolimod™ from its TLR5 Platform to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs SAN ANTONIO, April 28, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a late-stage immunotherapeutics company, today announced that it briefed senior officials at the U.S. Department of War on Entolimod™ for acute radiation syndrome. The briefing, facilitated by American Defense International (ADI), was presented to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs and his team at the Pentagon.

prnewswire.com - 2026-04-28 08:01:00

HOLMDEL, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, today announced that it has approved a 1-for-10 reverse stock split that will become effective with the commencement of trading on April 30, 2026.

globenewswire.com - 2026-04-28 07:59:00

Boston Trust Walden Corp decreased its position in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 5.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,838 shares of the medical research company's stock after selling 5,610 shares during the period. Boston

defenseworld.net - 2026-04-23 05:08:42